Histone deacetylases function as novel potential therapeutic targets for cancer

Hepatology Research

Volumn 47, Issue 2, 2017, Pages 149-159

  Zhang, Hui ^a   Shang, Yu Ping ^a   Chen, Hong Ying ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

cancer; histone deacetylase; histone deacetylase inhibitors; target

Indexed keywords

4 PHENYLBUTYRIC ACID; APICIDIN; BELINOSTAT; BUTYRIC ACID; DACINOSTAT; DEPSIPEPTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOCETINOSTAT; MYC PROTEIN; NOTCH RECEPTOR; OXAMFLATIN; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; ROMIDEPSIN; TACEDINALINE; TRANSCRIPTION FACTOR E2F; TRICHOSTATIN A; TUBACIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; WNT PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SPECIFICITY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASM; METASTASIS INHIBITION; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; UTERINE CERVIX CANCER;

EID: 84994032192     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12757     Document Type: Review

References (99)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
2. Han ZG. Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet 2012; 13: 171–205.
3. Comer BS, Ba M, Singer CA, Gerthoffer WT. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 2015; 147: 91–110.
4. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349–52.
5. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166–79.
6. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15–23.
7. Arts J, de Schepper S, Van Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 2003; 10: 2343–50.
8. Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012; 17: 191–204.
9. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19: 1049–66.
10. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85–94.
11. Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014; 71: 3885–901.
12. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737–74.
13. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17–31.
14. Guardiola AR, Yao TP. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 2002; 277: 3350–6.
15. McGuinness D, McGuinness DH, McCaul JA, Shiels PG. Sirtuins, bioageing, and cancer. J Aging Res 2011; 2011: 235754.
16. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69: 1702–5.
17. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32–42.
18. Adcock IM, Ford P, Ito K, Barnes PJ. Epigenetics and airways disease. Respir Res 2006; 7: 21.
19. Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 2005; 354: 107–20.
20. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001; 3: 4239–42.
21. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330–9.
22. Wang X, Xu J, Wang H et al. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial–mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun 2015; 456: 320–6.
23. Yang DH, Lee JW, Lee J, Moon EY. Dynamic rearrangement of F-actin is required to maintain the antitumor effect of trichostatin A. PLoS One 2014; 9: e97352.
24. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111–20.
25. Wang H, Zhou W, Zheng Z et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst) 2012; 11: 146–56.
26. Shin DY, Kim A, Kang HJ, Park S, Kim DW, Lee SS. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma. Cancer Lett 2015; 343: 89–97.
27. Abend A, Kehat I. Histone deacetylases as therapeutic targets – from cancer to cardiac disease. Pharmacol Ther 2015; 147: 55–62.
28. Wheler JJ, Janku F, Falchook GS et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 2014; 73: 495–501.
29. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4: 505–24.
30. Venza I, Visalli M, Oteri R, Teti D, Venza M. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol 2014; 21: 439–46.
31. Xie HJ, Noh JH, Kim JK et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One 2012; 7: e34265.
32. Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 2013; 19: 1173–81.
33. George P, Bali P, Annavarapu S et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768–76.
34. Tainer JA. Dynamic structures in DNA damage responses and cancer. Prog Biophys Mol Biol 2015; 117: 129–33.
35. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420–32.
36. Buurman R, Gurlevik E, Schaffer V et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012; 143: 811–20.e15.
37. Wu LM, Yang Z, Zhou L et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010; 5: e14460.
38. Liu C, Liu L, Shan J et al. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Lett 2013; 339: 60–9.
39. Bae HJ, Jung KH, Eun JW et al. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer. J Hepatol 2015; 63: 408–19.
40. Jung KH, Noh JH, Kim JK et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012; 56: 644–57.
41. Tian Y, Wong VW, Wong GL et al. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res 2015; 75: 4803–16.
42. Park BL, Kim YJ, Cheong HS et al. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 2007; 363: 776–81.
43. Lachenmayer A, Toffanin S, Cabellos L et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012; 56: 1343–50.
44. Zeng SS, Yamashita T, Kondo M et al. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 2014; 60: 127–34.
45. Chen MC, Huang HH, Lai CY et al. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotargets 2015; 7: 402–17.
46. Oiso H, Furukawa N, Suefuji M et al. The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver. Biochem Biophys Res Commun 2011; 404: 166–72.
47. Miyake K, Yoshizumi T, Imura S et al. Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008; 36: e1–e9.
48. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009; 277: 8–21.
49. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003; 310: 529–536.
50. Senese S, Zaragoza K, Minardi S et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784–95.
51. Kim JK, Noh JH, Eun JW et al. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol Cancer Res 2013; 11: 62–73.
52. Jiao F, Hu H, Yuan C, Jin Z, Guo Z, Wang L. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of p27, p53 and Bax. Int J Oncol 2014; 45: 1523–30.
53. Zuo Q, Wu W, Li X, Zhao L, Chen W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol Rep 2012; 27: 819–24.
54. Park SY, Jun JA, Jeong KJ et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011; 25: 1677–81.
55. Lehmann M, Hoffmann MJ, Koch A, Ulrich SM, Schulz WA, Niegisch G. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J Exp Clin Cancer Res 2014; 33: 59.
56. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168–76.
57. Kang ZH, Wang CY, Zhang WL et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One 2014; 9: e98894.
58. Liu Q, Zheng JM, Chen JK et al. Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1. Mol Med Rep 2014; 10: 2045–50.
59. Hutt DM, Herman D, Rodrigues AP et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6: 25–33.
60. Fleming JL, Dworkin AM, Allain DC et al. Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. Int J Cancer 2014; 134: 244–8.
61. Jin Z, Jiang W, Jiao F, Guo Z, Hu H, Wang L. Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients. Int J Clin Exp Pathol 2014; 7: 5872–9.
62. Song C, Zhu S, Wu C, Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J Biol Chem 2013; 288: 28021–33.
63. Liu H, Hu Q, Kaufman A, D'Ercole AJ, Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J Neurosci Res 2008; 86: 537–43.
64. Lindberg D, Akerstrom G, Westin G. Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol (Oxf) 2007; 66: 110–4.
65. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–7.
66. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9: 667–76.
67. Huang WJ, Lin CW, Lee CY et al. NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol 2011; 136: 156–67.
68. Ellis L, Ku SY, Ramakrishnan S et al. Combinatorial antitumor effect of HDAC and the PI3K–Akt–mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotargets 2013; 4: 2225–36.
69. Di Giorgio E, Clocchiatti A, Piccinin S et al. MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation. Mol Cell Biol 2013; 33: 4473–91.
70. Kurundkar D, Srivastava RK, Chaudhary SC et al. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 2013; 266: 233–44.
71. Wang G, Shi Y, Jiang X et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc Natl Acad Sci USA 2015; 112: 2853–58.
72. Hasty P, Christy BA. p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis 2013; 3. doi: 10.3402/pba.v3i0.22702.
73. Lin W, Tongyi S. Role of Bax/Bcl-2 family members in green tea polyphenol induced necroptosis of p53-deficient Hep3B cells. Tumour Biol 2014; 35: 8065–75.
74. Kloster MM, Naderi EH, Haaland I, Gjertsen BT, Blomhoff HK, Naderi S. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. Int J Oncol 2013; 42: 1815–21.
75. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011; 2: 456–62.
76. Brochier C, Dennis G, Rivieccio MA et al. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci 2013; 33: 8621–32.
77. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67: 3145–52.
78. Zhang YY, Zhou LM. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun 2012; 423: 26–31.
79. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013; 32: 599–609.
80. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod 2007; 22: 2956–66.
81. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours – lessons from the past. Nat Rev Clin Oncol 2013; 10: 256–66.
82. Zhang Y, Xu Q, Liu G et al. Effect of histone deacetylase on prostate carcinoma. Int J Clin Exp Pathol 2015; 8: 15030–34.
83. Wang Y, Zhang YL, Hennig K et al. Class I HDAC imaging using [(3)H]CI-994 autoradiography. Epigenetics 2013; 8: 756–764.
84. Chou DH, Holson EB, Wagner FF et al. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem Biol 2012; 19: 669–73.
85. Kramer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 2009; 30: 647–55.
86. Kong X, Fang M, Li P, Fang F, Xu Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J Mol Cell Cardiol 2009; 46: 292–9.
87. Zika E, Greer SF, Zhu XS, Ting JP. Histone deacetylase 1/mSin3A disrupts γ interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol 2003; 23: 3091–102.
88. Yu J, Qiu S, Ge Q et al. A novel SAHA–bendamustine hybrid induces apoptosis of leukemia cells. Oncotargets 2015; 6: 20 121–20131.
89. Wang Q, Tan R, Zhu X et al. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. Oncotargets 2016; 7: 10064–72.
90. Li L, Fan B, Zhang LH et al. Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer. Tumour Biol 2016. doi: 10.1007/s13277-016-4816-5.
91. Perego P, Zuco V, Gatti L, Zunino F. Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol 2012; 83: 987–94.
92. Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegeneration 2013; 8: 7.
93. Stronach EA, Alfraidi A, Rama N et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011; 71: 4412–22.
94. Moreno DA, Scrideli CA, Cortez MA et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 150: 665–73.
95. Kwiecinska P, Wrobel A, Tauboll E, Gregoraszczuk EL. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. Toxicol Lett 2014; 224: 225–32.
96. Deubzer HE, Schier MC, Oehme I et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013; 132: 2200–8.
97. Mottet D, Bellahcene A, Pirotte S et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 2007; 101: 1237–46.
98. Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009; 18: 1605–17.
99. Oehme I, Deubzer HE, Wegener D et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15: 91–9.